Anfibatide

DRUG4 trials

Sponsors

Lee's Pharmaceutical Limited

Conditions

Acquired Thrombotic Thrombocytopenic PurpuraCoagulation DisorderCoronary Heart DiseaseNon-ST Segment Elevation Myocardial InfarctionST Segment Elevation Myocardial Infarction

Phase 1

Anfibatide Phase Ib-IIa Clinical Trial

CompletedNCT01585259

Lee's Pharmaceutical LimitedNon-ST Segment Elevation Myocardial Infarction

Start: 2012-07-31End: 2015-07-31Updated: 2021-07-14

Anfibatide Phase 1 Clinical Trial in Healthy Volunteers

CompletedNCT01588132

Lee's Pharmaceutical LimitedCoagulation Disorder, Coronary Heart Disease

Start: 2010-09-30End: 2011-03-31Updated: 2012-04-30

Phase 2

Anfibatide Treatment in STEMI Patients

Lee's Pharmaceutical LimitedST Segment Elevation Myocardial Infarction

Start: 2015-08-31End: 2016-05-31Target: 240Updated: 2015-07-13

A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Lee's Pharmaceutical LimitedAcquired Thrombotic Thrombocytopenic Purpura

Start: 2019-07-31End: 2021-11-30Target: 74Updated: 2019-07-17

Related Papers

In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα.

2021-06-0331 citations